Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

  • by


  • Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B
  • The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration
  • Disarm is advancing its potent SARM1 inhibitors in preclinical development intending to deliver patients with peripheral neuropathy and other neurological diseases like ALS and MS

    Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly

The post Eli Lily to Acquire Disarm Therapeutics for ~.36B first appeared on PharmaShots.